Trial drug for biopsy-proven nonalcoholic steatohepatitis
Part of Digestive system, Hormones & metabolism clinical trials.
This Phase 2 trial studies HuHuangLianzonggan Capsule to treat nonalcoholic steatohepatitis (NASH), a liver inflammation caused by fat buildup. You may be eligible if you have confirmed NASH on a recent liver biopsy and meet specific liver fat, lab, and health-condition limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75 (men or women).
- You have NASH confirmed by liver biopsy within 6 months (or at screening), with a certain inflammation/fat score and fibrosis stage 1 to 3.
- MRI scan shows at least 8% liver fat (MRI-PDFF) at screening.
- You do not drink excessive alcohol in the past 12 months (limits differ for men vs. women).
- Your weight stayed stable (within 5% change) in the 6 months before screening, and you did not change diet/exercise in the 3 months before screening.
- You can consent in writing, and if you can become pregnant, you will use effective birth control and are not trying to get pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental pill called CS060380 for people with NASH (a type of fatty liver disease that can cause liver damage). You may qualify if you have a liver biopsy showing NASH with early-to-moderate scarring, or an MRI showing at least 10% liver fat, and your liver enzymes are stable.
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
This study tests a new injected drug (TQA2225/AP025) that may help reduce liver fat and inflammation in people with NASH (a type of fatty liver disease with scarring). It’s for adults who have had a recent liver biopsy and MRI confirming NASH and moderate liver fat.
This Phase 2 study tests whether SNP-610 (or a placebo) can improve non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. It also checks safety by comparing outcomes between the two groups.
This Phase 2 trial tests whether namodenoson can improve non-alcoholic steatohepatitis (NASH), a type of fatty liver inflammation. You may need two liver biopsies to see whether liver changes improve over time.
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Hear when a new NASH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.